News & Analysis on Clinical Trial Services & Contract Research And Development
Vertex, Jeffery Leiden, Reshma Kewalramni
By Maggie Lynch
- Last updated on
Jeffery Leiden, Vertex Pharmaceuticals current chairman, president, and CEO will transition into the role of executive chairman of the board in 2020.
The US-based biopharmaceutical company focused on drug design expects this move to occur in April 2020 as the company’s CMO Reshma Kewalramni will take over as President and CEO.
Leiden has sat on the board of directors for 10 years and has served as chairman and CEO since 2012. Bruce Sachs, lead independent director of Vertex’s board, said in regards to the move, “Jeff’s leadership has transformed Vertex and delivered extraordinary value for patients and shareholders through the discovery, development and commercialization of multiple transformative medicines.”
Previous to this role, Leiden worked as president and COO, CSO at Abbott Labs, and managing director at Clarus Funds.
Kewalramani has been with Vertex since 2017, after leaving Amgen where she was the VP and head of US medical organization. Leiden said, “Having worked closely with Reshma for the last several years, I know that she is tremendously talented, extremely passionate about our patient-centric mission, and fully prepared to lead Vertex as we enter our next phase as a company.”